2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness

Robyn Ralph; Jocelyne Lew; Tiansheng Zeng; Magie Francis; Bei Xue; Melissa Roux; Ali Toloue Ostadgavahi; Salvatore Rubino; Nicholas J. Dawe; Mohammed N. Al-Ahdal; David J. Kelvin; Christopher D. Richardson; Jason Kindrachuk; Darryl Falzarano; Alyson A. Kelvin

doi:10.3855/jidc.12425

2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness

Robyn Ralph, Jocelyne Lew, Tiansheng Zeng, Magie Francis, Bei Xue, Melissa Roux, Ali Toloue Ostadgavahi, Salvatore Rubino, Nicholas J. Dawe, Mohammed N. Al-Ahdal, David J. Kelvin, Christopher D. Richardson, Jason Kindrachuk, Darryl Falzarano, Alyson A. Kelvin

Medicine

Résultat de recherche: Article › examen par les pairs

141 Citations (Scopus)

Résumé

On 31 December 2019 the Wuhan Health Commission reported a cluster of atypical pneumonia cases that was linked to a wet market in the city of Wuhan, China. The first patients began experiencing symptoms of illness in mid-December 2019. Clinical isolates were found to contain a novel coronavirus with similarity to bat coronaviruses. As of 28 January 2020, there are in excess of 4,500 laboratory-confirmed cases, with > 100 known deaths. As with the SARS-CoV, infections in children appear to be rare. Travel-related cases have been confirmed in multiple countries and regions outside mainland China including Germany, France, Thailand, Japan, South Korea, Vietnam, Canada, and the United States, as well as Hong Kong and Taiwan. Domestically in China, the virus has also been noted in several cities and provinces with cases in all but one provinence. While zoonotic transmission appears to be the original source of infections, the most alarming development is that human-to-human transmission is now prevelant. Of particular concern is that many healthcare workers have been infected in the current epidemic. There are several critical clinical questions that need to be resolved, including how efficient is human-to-human transmission? What is the animal reservoir? Is there an intermediate animal reservoir? Do the vaccines generated to the SARS-CoV or MERS-CoV or their proteins offer protection against 2019-nCoV? We offer a research perspective on the next steps for the generation of vaccines. We also present data on the use of in silico docking in gaining insight into 2019-nCoV Spike-receptor binding to aid in therapeutic development. Diagnostic PCR protocols can be found at https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-coronavirus.

Langue d'origine	English
Pages (de-à)	3-17
Nombre de pages	15
Journal	Journal of Infection in Developing Countries
Volume	14
Numéro de publication	1
DOI	https://doi.org/10.3855/jidc.12425
Statut de publication	Published - 2020

Note bibliographique

Funding Information:
is funded by a Tier 2 Canada Research Chair in the Molecular Pathogenesis of Emerging and Re-Emerging Viruses provided by the Canadian Institutes of Health Research (Grant no. 950-231498). A.A.K. is funded by the IWK Health Centre (Grant no. 602975) and Nova Scotia Health Research Foundation (Grant no. 602932). DJK is a Tier 1 Canada Research Chair in Translational Vaccinology and Inflammation. Support for DJK was provided by LKSF, Canada Foundation for Innovation (JELF), and DMRF (Dalhousie Medical Research Foundation). VIDO-InterVac receives operational funding from the Government of Canada through Canada Foundation for Innovation – Major Science Initiatives and the Government of Saskatchewan through Innovation Saskatchewan. D.F. receives support from Canadian Institutes for Health Research (PJT 388665).

Funding Information:
Research into the novel coronavirus genome (2019-nCoV) was led by Dr. Yong-Zhen Zhang at the the Shanghai Public Health Clinical Center & School of Public Health, in collaboration with the Central Hospital of Wuhan, Huazhong University of Science and Technology, the Wuhan Center for Disease Control and Prevention, the National Institute for Communicable Disease Control and Prevention, the Chinese Center for Disease Control, and the University of Sydney, Sydney, Australia. We would like to thank and acknowledge the researchers who were working to identify this pathogen and make the data publically available. Specifically, we acknowledge the National Institute for Viral Disease Control and Prevention, China CDC; Wuhan Institute of Virology, Chinese Academy of Sciences; Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College; and Wuhan Jinyintan Hospital. In addition, we acknowledge GISAID (https://www.gisaid.org/) for providing a platform that allows data to be freely shared. J.K. is funded by a Tier 2 Canada Research Chair in the Molecular Pathogenesis of Emerging and Re-Emerging Viruses provided by the Canadian Institutes of Health Research (Grant no. 950-231498). A.A.K. is funded by the IWK Health Centre (Grant no. 602975) and Nova Scotia Health Research Foundation (Grant no. 602932). DJK is a Tier 1 Canada Research Chair in Translational Vaccinology and Inflammation. Support for DJK was provided by LKSF, Canada Foundation for Innovation (JELF), and DMRF (Dalhousie Medical Research Foundation). VIDO-InterVac receives operational funding from the Government of Canada through Canada Foundation for Innovation – Major Science Initiatives and the Government of Saskatchewan through Innovation Saskatchewan. D.F. receives support from Canadian Institutes for Health Research (PJT 388665).

Publisher Copyright:
Copyright © 2020 Ralph et al.

ASJC Scopus Subject Areas

Parasitology
Microbiology
Infectious Diseases
Virology

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.3855/jidc.12425

Autres fichiers et liens

Citer

Ralph, R., Lew, J., Zeng, T., Francis, M., Xue, B., Roux, M., Ostadgavahi, A. T., Rubino, S., Dawe, N. J., Al-Ahdal, M. N., Kelvin, D. J., Richardson, C. D., Kindrachuk, J., Falzarano, D., & Kelvin, A. A. (2020). 2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness. Journal of Infection in Developing Countries, 14(1), 3-17. https://doi.org/10.3855/jidc.12425

Ralph, R, Lew, J, Zeng, T, Francis, M, Xue, B, Roux, M, Ostadgavahi, AT, Rubino, S, Dawe, NJ, Al-Ahdal, MN, Kelvin, DJ , Richardson, CD, Kindrachuk, J, Falzarano, D & Kelvin, AA 2020, '2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness', Journal of Infection in Developing Countries, vol. 14, n° 1, pp. 3-17. https://doi.org/10.3855/jidc.12425

@article{2e9c66bef530403998218e20ab2f3ab8,

title = "2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness",

abstract = "On 31 December 2019 the Wuhan Health Commission reported a cluster of atypical pneumonia cases that was linked to a wet market in the city of Wuhan, China. The first patients began experiencing symptoms of illness in mid-December 2019. Clinical isolates were found to contain a novel coronavirus with similarity to bat coronaviruses. As of 28 January 2020, there are in excess of 4,500 laboratory-confirmed cases, with > 100 known deaths. As with the SARS-CoV, infections in children appear to be rare. Travel-related cases have been confirmed in multiple countries and regions outside mainland China including Germany, France, Thailand, Japan, South Korea, Vietnam, Canada, and the United States, as well as Hong Kong and Taiwan. Domestically in China, the virus has also been noted in several cities and provinces with cases in all but one provinence. While zoonotic transmission appears to be the original source of infections, the most alarming development is that human-to-human transmission is now prevelant. Of particular concern is that many healthcare workers have been infected in the current epidemic. There are several critical clinical questions that need to be resolved, including how efficient is human-to-human transmission? What is the animal reservoir? Is there an intermediate animal reservoir? Do the vaccines generated to the SARS-CoV or MERS-CoV or their proteins offer protection against 2019-nCoV? We offer a research perspective on the next steps for the generation of vaccines. We also present data on the use of in silico docking in gaining insight into 2019-nCoV Spike-receptor binding to aid in therapeutic development. Diagnostic PCR protocols can be found at https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-coronavirus.",

author = "Robyn Ralph and Jocelyne Lew and Tiansheng Zeng and Magie Francis and Bei Xue and Melissa Roux and Ostadgavahi, {Ali Toloue} and Salvatore Rubino and Dawe, {Nicholas J.} and Al-Ahdal, {Mohammed N.} and Kelvin, {David J.} and Richardson, {Christopher D.} and Jason Kindrachuk and Darryl Falzarano and Kelvin, {Alyson A.}",

note = "Funding Information: is funded by a Tier 2 Canada Research Chair in the Molecular Pathogenesis of Emerging and Re-Emerging Viruses provided by the Canadian Institutes of Health Research (Grant no. 950-231498). A.A.K. is funded by the IWK Health Centre (Grant no. 602975) and Nova Scotia Health Research Foundation (Grant no. 602932). DJK is a Tier 1 Canada Research Chair in Translational Vaccinology and Inflammation. Support for DJK was provided by LKSF, Canada Foundation for Innovation (JELF), and DMRF (Dalhousie Medical Research Foundation). VIDO-InterVac receives operational funding from the Government of Canada through Canada Foundation for Innovation – Major Science Initiatives and the Government of Saskatchewan through Innovation Saskatchewan. D.F. receives support from Canadian Institutes for Health Research (PJT 388665). Funding Information: Research into the novel coronavirus genome (2019-nCoV) was led by Dr. Yong-Zhen Zhang at the the Shanghai Public Health Clinical Center & School of Public Health, in collaboration with the Central Hospital of Wuhan, Huazhong University of Science and Technology, the Wuhan Center for Disease Control and Prevention, the National Institute for Communicable Disease Control and Prevention, the Chinese Center for Disease Control, and the University of Sydney, Sydney, Australia. We would like to thank and acknowledge the researchers who were working to identify this pathogen and make the data publically available. Specifically, we acknowledge the National Institute for Viral Disease Control and Prevention, China CDC; Wuhan Institute of Virology, Chinese Academy of Sciences; Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College; and Wuhan Jinyintan Hospital. In addition, we acknowledge GISAID (https://www.gisaid.org/) for providing a platform that allows data to be freely shared. J.K. is funded by a Tier 2 Canada Research Chair in the Molecular Pathogenesis of Emerging and Re-Emerging Viruses provided by the Canadian Institutes of Health Research (Grant no. 950-231498). A.A.K. is funded by the IWK Health Centre (Grant no. 602975) and Nova Scotia Health Research Foundation (Grant no. 602932). DJK is a Tier 1 Canada Research Chair in Translational Vaccinology and Inflammation. Support for DJK was provided by LKSF, Canada Foundation for Innovation (JELF), and DMRF (Dalhousie Medical Research Foundation). VIDO-InterVac receives operational funding from the Government of Canada through Canada Foundation for Innovation – Major Science Initiatives and the Government of Saskatchewan through Innovation Saskatchewan. D.F. receives support from Canadian Institutes for Health Research (PJT 388665). Publisher Copyright: Copyright {\textcopyright} 2020 Ralph et al.",

year = "2020",

doi = "10.3855/jidc.12425",

language = "English",

volume = "14",

pages = "3--17",

journal = "Journal of Infection in Developing Countries",

issn = "2036-6590",

publisher = "Journal of Infection in Developing Countries",

number = "1",

}

TY - JOUR

T1 - 2019-nCoV (Wuhan virus), a novel Coronavirus

T2 - Human-to-human transmission, travel-related cases, and vaccine readiness

AU - Ralph, Robyn

AU - Lew, Jocelyne

AU - Zeng, Tiansheng

AU - Francis, Magie

AU - Xue, Bei

AU - Roux, Melissa

AU - Ostadgavahi, Ali Toloue

AU - Rubino, Salvatore

AU - Dawe, Nicholas J.

AU - Al-Ahdal, Mohammed N.

AU - Kelvin, David J.

AU - Richardson, Christopher D.

AU - Kindrachuk, Jason

AU - Falzarano, Darryl

AU - Kelvin, Alyson A.

N1 - Funding Information: is funded by a Tier 2 Canada Research Chair in the Molecular Pathogenesis of Emerging and Re-Emerging Viruses provided by the Canadian Institutes of Health Research (Grant no. 950-231498). A.A.K. is funded by the IWK Health Centre (Grant no. 602975) and Nova Scotia Health Research Foundation (Grant no. 602932). DJK is a Tier 1 Canada Research Chair in Translational Vaccinology and Inflammation. Support for DJK was provided by LKSF, Canada Foundation for Innovation (JELF), and DMRF (Dalhousie Medical Research Foundation). VIDO-InterVac receives operational funding from the Government of Canada through Canada Foundation for Innovation – Major Science Initiatives and the Government of Saskatchewan through Innovation Saskatchewan. D.F. receives support from Canadian Institutes for Health Research (PJT 388665). Funding Information: Research into the novel coronavirus genome (2019-nCoV) was led by Dr. Yong-Zhen Zhang at the the Shanghai Public Health Clinical Center & School of Public Health, in collaboration with the Central Hospital of Wuhan, Huazhong University of Science and Technology, the Wuhan Center for Disease Control and Prevention, the National Institute for Communicable Disease Control and Prevention, the Chinese Center for Disease Control, and the University of Sydney, Sydney, Australia. We would like to thank and acknowledge the researchers who were working to identify this pathogen and make the data publically available. Specifically, we acknowledge the National Institute for Viral Disease Control and Prevention, China CDC; Wuhan Institute of Virology, Chinese Academy of Sciences; Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College; and Wuhan Jinyintan Hospital. In addition, we acknowledge GISAID (https://www.gisaid.org/) for providing a platform that allows data to be freely shared. J.K. is funded by a Tier 2 Canada Research Chair in the Molecular Pathogenesis of Emerging and Re-Emerging Viruses provided by the Canadian Institutes of Health Research (Grant no. 950-231498). A.A.K. is funded by the IWK Health Centre (Grant no. 602975) and Nova Scotia Health Research Foundation (Grant no. 602932). DJK is a Tier 1 Canada Research Chair in Translational Vaccinology and Inflammation. Support for DJK was provided by LKSF, Canada Foundation for Innovation (JELF), and DMRF (Dalhousie Medical Research Foundation). VIDO-InterVac receives operational funding from the Government of Canada through Canada Foundation for Innovation – Major Science Initiatives and the Government of Saskatchewan through Innovation Saskatchewan. D.F. receives support from Canadian Institutes for Health Research (PJT 388665). Publisher Copyright: Copyright © 2020 Ralph et al.

PY - 2020

Y1 - 2020

N2 - On 31 December 2019 the Wuhan Health Commission reported a cluster of atypical pneumonia cases that was linked to a wet market in the city of Wuhan, China. The first patients began experiencing symptoms of illness in mid-December 2019. Clinical isolates were found to contain a novel coronavirus with similarity to bat coronaviruses. As of 28 January 2020, there are in excess of 4,500 laboratory-confirmed cases, with > 100 known deaths. As with the SARS-CoV, infections in children appear to be rare. Travel-related cases have been confirmed in multiple countries and regions outside mainland China including Germany, France, Thailand, Japan, South Korea, Vietnam, Canada, and the United States, as well as Hong Kong and Taiwan. Domestically in China, the virus has also been noted in several cities and provinces with cases in all but one provinence. While zoonotic transmission appears to be the original source of infections, the most alarming development is that human-to-human transmission is now prevelant. Of particular concern is that many healthcare workers have been infected in the current epidemic. There are several critical clinical questions that need to be resolved, including how efficient is human-to-human transmission? What is the animal reservoir? Is there an intermediate animal reservoir? Do the vaccines generated to the SARS-CoV or MERS-CoV or their proteins offer protection against 2019-nCoV? We offer a research perspective on the next steps for the generation of vaccines. We also present data on the use of in silico docking in gaining insight into 2019-nCoV Spike-receptor binding to aid in therapeutic development. Diagnostic PCR protocols can be found at https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-coronavirus.

AB - On 31 December 2019 the Wuhan Health Commission reported a cluster of atypical pneumonia cases that was linked to a wet market in the city of Wuhan, China. The first patients began experiencing symptoms of illness in mid-December 2019. Clinical isolates were found to contain a novel coronavirus with similarity to bat coronaviruses. As of 28 January 2020, there are in excess of 4,500 laboratory-confirmed cases, with > 100 known deaths. As with the SARS-CoV, infections in children appear to be rare. Travel-related cases have been confirmed in multiple countries and regions outside mainland China including Germany, France, Thailand, Japan, South Korea, Vietnam, Canada, and the United States, as well as Hong Kong and Taiwan. Domestically in China, the virus has also been noted in several cities and provinces with cases in all but one provinence. While zoonotic transmission appears to be the original source of infections, the most alarming development is that human-to-human transmission is now prevelant. Of particular concern is that many healthcare workers have been infected in the current epidemic. There are several critical clinical questions that need to be resolved, including how efficient is human-to-human transmission? What is the animal reservoir? Is there an intermediate animal reservoir? Do the vaccines generated to the SARS-CoV or MERS-CoV or their proteins offer protection against 2019-nCoV? We offer a research perspective on the next steps for the generation of vaccines. We also present data on the use of in silico docking in gaining insight into 2019-nCoV Spike-receptor binding to aid in therapeutic development. Diagnostic PCR protocols can be found at https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-coronavirus.

UR - http://www.scopus.com/inward/record.url?scp=85079141403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079141403&partnerID=8YFLogxK

U2 - 10.3855/jidc.12425

DO - 10.3855/jidc.12425

M3 - Article

C2 - 32088679

AN - SCOPUS:85079141403

SN - 2036-6590

VL - 14

SP - 3

EP - 17

JO - Journal of Infection in Developing Countries

JF - Journal of Infection in Developing Countries

IS - 1

ER -

2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness

Résumé

Note bibliographique

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer